If you sell services to industry sponsors, roughly half of what a trial registry hands back is noise. Search a therapeutic area in the UK or continental Europe and the results fill with university hospitals, national health bodies and academic consortia. A business development lead at a UK CRO put it plainly: the vast majority are university hospitals, which are not really that applicable to us.
They are not wrong, and it is not a data-quality problem. It is what the registry is for. Public trial registries exist to make every interventional study visible, whoever runs it. Commercial sponsorship is one slice of that, and in some regions it is the smaller slice.
Here is how sponsor class works, why the geographic skew happens, and what you can do about it today.
Sponsor class in the registry
ClinicalTrials.gov records a funder type for each study. The values that matter for a commercial BD team are:
| Funder type | What it usually means | Worth prospecting? |
|---|---|---|
| Industry | A company is the lead sponsor and is paying | Yes, this is the target |
| NIH | US federal funding, academic or government-run | Rarely |
| Other US Federal | Other federal agencies | Rarely |
| Other | Universities, hospitals, foundations, individual investigators | Usually not, with exceptions |
The trap sits in that last row. "Other" is a very large bucket. It holds university hospitals and investigator-initiated studies, which you probably do not want. It also holds small private biotechs that did not classify themselves as industry, foundations that fund real outsourced work, and the occasional well-funded non-profit that buys services exactly like a company does.
So sponsor class is a strong first filter and a weak final one. Treat it as a way to cut volume, not as a definition of your addressable market.
Lead sponsor versus collaborator
The second thing that trips people up is the difference between the lead sponsor and the collaborators.
A study can be led by a university and collaborated on by a pharmaceutical company. The company may be supplying the drug, funding part of the work, or both. If you filter on lead sponsor only, you will miss these entirely. If you filter on any-sponsor, you will pull in every study where a large pharma name appears in a supporting role, and most of those are not buying anything.
The practical rule: filter on lead sponsor for outbound, then review collaborators separately when you are researching a named account. A company that shows up as a collaborator on six academic studies in your therapeutic area is running a real programme, even if it leads none of them.
Why UK and EU results skew academic
Three things compound in Europe.
Academic medical centres run a larger share of early-phase work than they do in the US. National health systems register studies that in other markets would never reach a public registry. And European biotechs are on average smaller and earlier, so more of their work is done in partnership with a hospital that takes the lead-sponsor slot.
The result is that the same search returns a very different mix depending on geography. A US oncology search might come back majority industry. The equivalent UK search often does not. If your territory is European and your outbound assumes a US-shaped result set, your list quality will be worse and you will not know why.
Doing it today
Sponsor class is one input rather than the whole answer. The approach that works is a combination of filters:
- Filter by company attributes rather than study attributes. Filter the sponsor universe by therapeutic area, highest phase and modality. Companies that carry a modality and a development pipeline are, almost by definition, not university hospitals.
- Use HQ country to shape the list, then accept that a European list needs more manual review than a US one.
- Scan the names. This sounds crude and it is, but it is fast. Academic sponsors announce themselves in their names: university, hospital, centre hospitalier, universitätsklinikum, foundation, institute. A BD rep can clear a hundred-row list in ten minutes.
- Keep a rejection list. Whatever tool you use, record the academic sponsors you have already dismissed so nobody on your team re-qualifies them next quarter. This is the step most teams skip and the one that compounds.
See Salesmotion on a real account
Book a 15-minute demo and see how your team saves hours on account research.
The edge cases nobody solves
No filter resolves the edge cases, because they are genuine ambiguity rather than missing data. A foundation that funds and outsources a Phase 2 programme looks like an academic sponsor in the registry and behaves like an industry one in your pipeline. A small biotech that classified itself as "Other" during registration is an industry sponsor wearing the wrong label.
Any vendor promising you a clean industry-only universe is either filtering aggressively and hiding the misses, or has not looked closely at the data. The realistic goal is a list that is eighty to ninety percent on-target before a human reads it, rather than the forty or fifty percent you get from an unfiltered registry search.
Frequently asked questions
How do I filter academic sponsors out? Filter the sponsor universe on therapeutic area, phase, modality and HQ. That excludes most academic centres in one step, because a university hospital does not carry a development pipeline the way a company does, and it is a better first cut than sponsor class alone.
Does the skew affect US searches too? Less, but yes. The NIH funder type makes federal funding easy to spot in the US, and a larger share of US early-phase work is company-led. European searches need more review.
Should I ignore academic sponsors entirely? No. Some academic centres and foundations outsource real work on real budgets, and a few are excellent long-term accounts. The point is not to exclude them permanently but to stop them crowding out industry sponsors in a prospecting list, which is a different job from account management.
What about collaborator relationships? Filter on lead sponsor for outbound, then check collaborators when researching a named account. A company appearing repeatedly as a collaborator in your therapeutic area has a programme worth understanding even if it leads no studies itself.
If your territory is European and your list keeps filling with hospitals, it is worth seeing what a filtered sponsor universe looks like on your actual therapeutic areas. That is the fastest way to judge whether the current filters get you close enough. See how it works for CRO business development.
